华中科技大学学报(医学版)
華中科技大學學報(醫學版)
화중과기대학학보(의학판)
ACTA UNIVERSITATIS MEDICINAE TONGJI
2015年
1期
74-77
,共4页
舒榕%王强%朱慧芬%孙媛丽%贺琪%万京华
舒榕%王彊%硃慧芬%孫媛麗%賀琪%萬京華
서용%왕강%주혜분%손원려%하기%만경화
次级淋巴组织趋化因子%Birc5%siRNA%肿瘤
次級淋巴組織趨化因子%Birc5%siRNA%腫瘤
차급림파조직추화인자%Birc5%siRNA%종류
secondary lymphoid-tissue chemokine%Birc5%siRNA%tumor
目的:构建携带SLC基因的Birc5‐siRNA质粒载体,为肿瘤靶向治疗研究提供基础。方法使用Ambion公司siRNATarget Finder设计的Birc5 mRNA干扰序列,将Birc5‐siRNA插入载体 PEGFP6‐1后转化大肠埃希菌扩增培养,提取质粒;将SLC插入质粒pGenesil‐8后转化细菌扩增培养,提取质粒;挑取酶切鉴定正确的质粒转化菌液测序鉴定;采用分子克隆技术构建特异性沉默Birc5且携带SLC基因的质粒,命名为pgsiRNA‐Birc5+SLC。结果质粒Birc5能被 EcoRⅠ酶切出1条约400 bp的DNA条带,说明Birc5‐siRNA 已插入质粒载体PEGFP6‐1;pGenesil‐8‐SLC能被BglⅡ+ XbaⅠ酶切出1条约430 bp的DNA条带,说明SLC插入正确;酶切鉴定正确的质粒转化菌液Birc5‐siRNA和SLC测序结果显示均为插入正确的克隆质粒;经酶切鉴定分析显示pgsiRNA‐Birc5+SLC符合酶切鉴定结果,表明携带SLC基因的Birc5‐siRNA质粒载体构建成功。结论成功构建了携带SLC基因的Birc5‐siRNA质粒,为进一步研究靶向沉默肿瘤Birc5基因并趋化淋巴细胞抗肿瘤研究提供了工具和基础。
目的:構建攜帶SLC基因的Birc5‐siRNA質粒載體,為腫瘤靶嚮治療研究提供基礎。方法使用Ambion公司siRNATarget Finder設計的Birc5 mRNA榦擾序列,將Birc5‐siRNA插入載體 PEGFP6‐1後轉化大腸埃希菌擴增培養,提取質粒;將SLC插入質粒pGenesil‐8後轉化細菌擴增培養,提取質粒;挑取酶切鑒定正確的質粒轉化菌液測序鑒定;採用分子剋隆技術構建特異性沉默Birc5且攜帶SLC基因的質粒,命名為pgsiRNA‐Birc5+SLC。結果質粒Birc5能被 EcoRⅠ酶切齣1條約400 bp的DNA條帶,說明Birc5‐siRNA 已插入質粒載體PEGFP6‐1;pGenesil‐8‐SLC能被BglⅡ+ XbaⅠ酶切齣1條約430 bp的DNA條帶,說明SLC插入正確;酶切鑒定正確的質粒轉化菌液Birc5‐siRNA和SLC測序結果顯示均為插入正確的剋隆質粒;經酶切鑒定分析顯示pgsiRNA‐Birc5+SLC符閤酶切鑒定結果,錶明攜帶SLC基因的Birc5‐siRNA質粒載體構建成功。結論成功構建瞭攜帶SLC基因的Birc5‐siRNA質粒,為進一步研究靶嚮沉默腫瘤Birc5基因併趨化淋巴細胞抗腫瘤研究提供瞭工具和基礎。
목적:구건휴대SLC기인적Birc5‐siRNA질립재체,위종류파향치료연구제공기출。방법사용Ambion공사siRNATarget Finder설계적Birc5 mRNA간우서렬,장Birc5‐siRNA삽입재체 PEGFP6‐1후전화대장애희균확증배양,제취질립;장SLC삽입질립pGenesil‐8후전화세균확증배양,제취질립;도취매절감정정학적질립전화균액측서감정;채용분자극륭기술구건특이성침묵Birc5차휴대SLC기인적질립,명명위pgsiRNA‐Birc5+SLC。결과질립Birc5능피 EcoRⅠ매절출1조약400 bp적DNA조대,설명Birc5‐siRNA 이삽입질립재체PEGFP6‐1;pGenesil‐8‐SLC능피BglⅡ+ XbaⅠ매절출1조약430 bp적DNA조대,설명SLC삽입정학;매절감정정학적질립전화균액Birc5‐siRNA화SLC측서결과현시균위삽입정학적극륭질립;경매절감정분석현시pgsiRNA‐Birc5+SLC부합매절감정결과,표명휴대SLC기인적Birc5‐siRNA질립재체구건성공。결론성공구건료휴대SLC기인적Birc5‐siRNA질립,위진일보연구파향침묵종류Birc5기인병추화림파세포항종류연구제공료공구화기출。
Objective To construct the Birc5‐siRNA vector carrying SLC in order to provide a basis for the research on tumor biological targeted therapy.Methods Interfering sequences of Birc5 were designed by using Ambion Target Finder.The Birc5‐siRNA was inserted into PEGFP6‐1 ,and then transformed and cultured with E. coli. Afterwards ,the plasmid was extrac‐ted and identified.SLC was inserted into pGenesil‐8 ,which was transformed ,cultured with E. coli ,followed by the extraction and identification of the plasmid. The bacterial transformation solution was selected after identification with enzyme diges‐tion. The plasmid that silenced Birc5 and carried SLC was constructed by molecular cloning technology and named pgsiRNA‐Birc5+SLC. Results The plasmid Birc5 was cleaved by EcoRⅠ,resulting in a 400 bp DNA strip ,indicating that Birc5‐siRNA was insert‐ed into PEGFP6‐1. Plasmid pGenesil‐8‐SLC was cleaved by BglⅡ+ XbaⅠto form a 430 bp DNA strip ,which suggested that SLC was in‐serted into pGenesil‐8.The sequences of the recombinant plasmid were proved to be completely correct.Restriction enzyme analysis showed the Birc5‐siRNA plasmid carrying SLC was successfully constructed.Conclusion The Birc5‐siRNA plasmid carrying SLC was successfully constructed ,which provides a tool and basis for further study of tumor targeted therapy aimed at SLC and Birc 5.